MedTrace Logo

A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes

NCT02008851 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2014-12-11

No results posted yet for this study

Summary

The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.

Conditions

Interventions

BIOLOGICAL

Neo-kidney augment

Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient

Sponsors & Collaborators

  • Tengion

    lead INDUSTRY

Principal Investigators

  • Eric McAllister, MD, DPhil · Tengion, Inc.

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02008851 on ClinicalTrials.gov